David W. Fry
Impact in
- Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Organic Chemistry top 0.5%
- Quinazolinone synthesis and applications
- Synthesis and biological activity
Papers in
-
- Cancer therapeutics and mechanisms 17
- Biochemical and Molecular Research 12
- PI3K/AKT/mTOR signaling in cancer 11
- Oncology 62
- HER2/EGFR in Cancer Research 35
- Co-authors
- Alexander J. Bridges (18 shared papers)Wilbur R. Leopold (20 shared papers)I. David Goldman (14 shared papers)James M. Nelson (13 shared papers)Alan J. Kraker (10 shared papers)Amy McMichael (8 shared papers)Paul R. Keller (10 shared papers)William A. Denny (18 shared papers)
- Journals
- Journal of Medicinal Chemistry (26 papers)Journal of Clinical Oncology (6 papers)Biochemical Pharmacology (5 papers)Journal of Biological Chemistry (5 papers)Cancer Chemotherapy and Pharmacology (3 papers)
- Partner nations
- United StatesNew ZealandUnited Kingdom
In The Last Decade
David W. Fry
121 papers receiving 8.1k citations
David W. Fry's Hit Papers
Peers
Comparison fields: 5 of 135
- Oncology 3.3k
- Organic Chemistry 2.2k
- Immunology and Allergy 423
- Molecular Biology 3.8k
- Pulmonary and Respiratory Medicine 1.6k
Countries citing papers authored by David W. Fry
This map shows the geographic impact of David W. Fry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David W. Fry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David W. Fry more than expected).
Fields of papers citing papers by David W. Fry
This network shows the impact of papers produced by David W. Fry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David W. Fry. The network helps show where David W. Fry may publish in the future.
Co-authors
The 25 scholars most cited alongside David W. Fry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 123 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts Hit paper breakdown → | 2004 | 989 |
| 2 | A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase Hit paper breakdown → | 1994 | 685 |
| 3 | 2005 | 392 | |
| 4 | 1978 | 388 | |
| 5 | 1999 | 350 | |
| 6 | 1998 | 345 | |
| 7 | 1996 | 288 | |
| 8 | 1995 | 224 | |
| 9 | PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. | 1997 | 176 |
| 10 | 1982 | 172 | |
| 11 | 1999 | 159 | |
| 12 | 1998 | 139 | |
| 13 | 1996 | 135 | |
| 14 | 2000 | 130 | |
| 15 | 1995 | 127 | |
| 16 | 2005 | 122 | |
| 17 | 2020 | 112 | |
| 18 | 1999 | 101 | |
| 19 | 1999 | 101 | |
| 20 | 1988 | 101 |
About David W. Fry
David W. Fry is a scholar working on Molecular Biology, Oncology, Organic Chemistry, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 123 papers that have together received 8.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (35 papers), Quinazolinone synthesis and applications (19 papers), Cancer therapeutics and mechanisms (17 papers), Synthesis and biological activity (16 papers), Synthesis and Characterization of Heterocyclic Compounds (16 papers), Lung Cancer Treatments and Mutations (12 papers), Biochemical and Molecular Research (12 papers) and PI3K/AKT/mTOR signaling in cancer (11 papers). The work is most often cited by research in Oncology (3.3k citations), Organic Chemistry (2.2k citations), Immunology and Allergy (423 citations), Molecular Biology (3.8k citations) and Pulmonary and Respiratory Medicine (1.6k citations). David W. Fry has collaborated with scholars based in United States, New Zealand and United Kingdom. Frequent co-authors include Alexander J. Bridges, Wilbur R. Leopold, I. David Goldman, James M. Nelson, Alan J. Kraker, Amy McMichael, Paul R. Keller, William A. Denny, William L. Elliott and Gordon W. Rewcastle. Their work appears in journals such as Journal of Medicinal Chemistry, Journal of Clinical Oncology, Biochemical Pharmacology, Journal of Biological Chemistry and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.